363 related articles for article (PubMed ID: 35412162)
21. Comparison of the Psychometric Properties of the EQ-5D-3L-Y and EQ-5D-5L-Y Instruments in Spanish Children and Adolescents.
Pérez-Sousa MÁ; Olivares PR; Ramírez-Vélez R; Gusi N
Value Health; 2021 Dec; 24(12):1799-1806. PubMed ID: 34838278
[TBL] [Abstract][Full Text] [Related]
22. Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing.
Zhu J; Yan XX; Liu CC; Wang H; Wang L; Cao SM; Liao XZ; Xi YF; Ji Y; Lei L; Xiao HF; Guan HJ; Wei WQ; Dai M; Chen W; Shi JF
Qual Life Res; 2021 Mar; 30(3):841-854. PubMed ID: 32930993
[TBL] [Abstract][Full Text] [Related]
23. Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece.
Yfantopoulos JN; Chantzaras AE
Eur J Health Econ; 2017 May; 18(4):519-531. PubMed ID: 27262480
[TBL] [Abstract][Full Text] [Related]
24. Health-related quality of life in patients with lower limb amputation - an assessment of the measurement properties of EQ-5D-3L and EQ-5D-5L using data from the Swedish Amputation and Prosthetics Registry.
Ernstsson O; Hagberg K; Janssen MF; Bonsel GJ; Korkmaz S; Zethraeus N; Heintz E
Disabil Rehabil; 2022 Dec; 44(26):8471-8479. PubMed ID: 34932426
[TBL] [Abstract][Full Text] [Related]
25. A head-to-head comparison of the EQ-5D-5L and 15D descriptive systems and index values in a general population sample.
Nikl A; Janssen MF; Brodszky V; Rencz F
Health Qual Life Outcomes; 2023 Feb; 21(1):17. PubMed ID: 36803866
[TBL] [Abstract][Full Text] [Related]
26. Psychometric properties comparison between EQ-5D-5L and EQ-5D-3L in the general Thai population.
Kangwanrattanakul K; Parmontree P
Qual Life Res; 2020 Dec; 29(12):3407-3417. PubMed ID: 32780315
[TBL] [Abstract][Full Text] [Related]
27. General and Skin-Specific Health-Related Quality of Life in Patients With Atopic Dermatitis Before and During the COVID-19 Pandemic.
Koszorú K; Hajdu K; Brodszky V; Szabó Á; Borza J; Bodai K; Pónyai G; Szegedi A; Sárdy M; Rencz F
Dermatitis; 2022 Nov-Dec 01; 33(6S):S92-S103. PubMed ID: 35674639
[TBL] [Abstract][Full Text] [Related]
28. A Direct Comparison of the Measurement Properties of EQ-5D-5L, PROMIS-29+2 and PROMIS Global Health Instruments and EQ-5D-5L and PROPr Utilities in a General Population Sample.
Rencz F; Brodszky V; Janssen MF
Value Health; 2023 Jul; 26(7):1045-1056. PubMed ID: 36804583
[TBL] [Abstract][Full Text] [Related]
29. Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa.
Gergely LH; Gáspár K; Brodszky V; Kinyó Á; Szegedi A; Remenyik É; Kiss NF; Bató A; Péntek M; Gulácsi L; Sárdy M; Bánvölgyi A; Wikonkál N; Rencz F
J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2584-2592. PubMed ID: 32618022
[TBL] [Abstract][Full Text] [Related]
30. Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis.
Lin J; Wong CKH; Cheung JPY; Cheung PWH; Luo N
Eur J Health Econ; 2022 Nov; 23(8):1383-1395. PubMed ID: 35122171
[TBL] [Abstract][Full Text] [Related]
31. Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases.
Scalone L; Ciampichini R; Fagiuoli S; Gardini I; Fusco F; Gaeta L; Del Prete A; Cesana G; Mantovani LG
Qual Life Res; 2013 Sep; 22(7):1707-16. PubMed ID: 23192232
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the three-level and the five-level versions of the EQ-5D.
Christiansen ASJ; Møller MLS; Kronborg C; Haugan KJ; Køber L; Højberg S; Brandes A; Graff C; Diederichsen SZ; Nielsen JB; Krieger D; Holst AG; Svendsen JH
Eur J Health Econ; 2021 Jun; 22(4):621-628. PubMed ID: 33733344
[TBL] [Abstract][Full Text] [Related]
33. EQ-5D-Y-3L and EQ-5D-Y-5L proxy report: psychometric performance and agreement with self-report.
Fitriana TS; Purba FD; Stolk E; Busschbach JJV
Health Qual Life Outcomes; 2022 Jun; 20(1):88. PubMed ID: 35659313
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the EQ-5D-3L and 5L versions in low back pain patients.
Garratt AM; Furunes H; Hellum C; Solberg T; Brox JI; Storheim K; Johnsen LG
Health Qual Life Outcomes; 2021 May; 19(1):155. PubMed ID: 34049574
[TBL] [Abstract][Full Text] [Related]
35. Investigating the psychometric properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, CHU-9D, and PedsQL in children and adolescents with osteogenesis imperfecta.
Xu RH; Zhu L; Sun R; Tan RL; Luo N; Zou S; Dong D
Eur J Pediatr; 2022 Dec; 181(12):4049-4058. PubMed ID: 36156120
[TBL] [Abstract][Full Text] [Related]
36. A head-to-head comparison of measurement properties of the EQ-5D-3L and EQ-5D-5L in acute myeloid leukemia patients.
Yu H; Zeng X; Sui M; Liu R; Tan RL; Yang J; Huang W; Luo N
Qual Life Res; 2021 Mar; 30(3):855-866. PubMed ID: 32965633
[TBL] [Abstract][Full Text] [Related]
37. The EQ-5D-5L is More Discriminative Than the EQ-5D-3L in Patients with Diabetes in Singapore.
Wang P; Luo N; Tai ES; Thumboo J
Value Health Reg Issues; 2016 May; 9():57-62. PubMed ID: 27881260
[TBL] [Abstract][Full Text] [Related]
38. Comparing Measurement Properties of the English EQ-5D-Y 3-Level Version With the 5-Level Version in South Africa.
Verstraete J; Amien R; Scott D
Value Health Reg Issues; 2022 Jul; 30():140-147. PubMed ID: 35429927
[TBL] [Abstract][Full Text] [Related]
39. Psychometric performance of the Chichewa versions of the EQ-5D-Y-3L and EQ-5D-Y-5L among healthy and sick children and adolescents in Malawi.
Ngwira LG; Maheswaran H; Verstraete J; Petrou S; Niessen L; Smith SC
J Patient Rep Outcomes; 2023 Mar; 7(1):22. PubMed ID: 36892714
[TBL] [Abstract][Full Text] [Related]
40. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
